Savara Inc., a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, announced that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File (RTF) letter for their Biologics License Application $(BLA.AU)$ for MOLBREEVI, a treatment for autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP). The FDA's decision was based on the need for additional Chemistry, Manufacturing, and Controls $(CMC)$ data, not due to safety issues. Savara plans to address the FDA's request and resubmit the BLA by the fourth quarter of 2025. The company has emphasized its confidence in MOLBREEVI's potential, supported by clinical data. Despite the RTF, previous regulatory designations, including Fast Track and Breakthrough Therapy, remain in effect. Savara is also advancing its strategy to establish a redundant supply chain and has made significant progress with its manufacturing processes.